Moderna beats estimates but slashes guidance on low EU sales, competitive U.S. vaccine market
Moderna(MRNA) CNBC·2024-08-01 10:34
The Moderna Inc. headquarters in Cambridge, Massachusetts, US, on Tuesday, March 26, 2024. Moderna on Thursday reported second-quarter revenue that beat expectations but slashed its full-year sales guidance, citing lower expected sales in Europe, a "competitive environment" for respiratory vaccines in the U.S. and the potential for deferred international revenue into 2025. The biotech company now expects 2024 product revenue to come in between $3 billion to $3.5 billion, down from a previous guidance of $4 ...